All In Biotech

Drug Trial Radar · NCT01252719

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

Last checked: Nov 19, 2026Latest source record: Aug 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 968 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

968

Actual

Start

Dec 2010

Primary completion

Oct 2012

Study completion Nov 30, 2012

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 trial was to evaluate the efficacy, safety, and tolerability of oritavancin in acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant staphylococcus aureus (MRSA), and to evaluate the potential economic benefit of oritavancin administered as a single 1200-milligram (mg) intravenous (IV) dose.

Conditions

  • Wound Infection
  • Abscess
  • Systemic Inflammation
  • Cellulitis

Interventions

  • Single-Dose IV Oritavancin DiphosphateDrug

    Oritavancin was administered as a single IV dose.

  • IV VancomycinDrug

    Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.

  • PlaceboDrug

    Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)Time frame: 48-72 hours after the initiation of study therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sharp Chula Vista Medical Center

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.